ADReCS

Pharmaceutical Information

Drug Name	Nevirapine
Drug ID	BADD_D01557
Description	A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage	For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status	approved
ATC Code	J05AG01
DrugBank ID	DB00238
KEGG ID	D00435
MeSH ID	D019829
PubChem ID	4463
TTD Drug ID	D0O2EM
NDC Product Code	53104-7546; 70159-002; 65862-027; 0378-4050; 64380-709; 65862-932; 65862-933; 31722-505; 65862-057; 68554-0044; 33342-004; 0597-0047; 64220-102; 0378-4890; 65162-209; 33342-238; 42571-131
UNII	99DK7FVK1H
Synonyms	Nevirapine \| Nevirapine Hemihydrate \| Hemihydrate, Nevirapine \| Viramune \| BI-RG-587 \| BI RG 587 \| BIRG587

Chemical Information

Molecular Formula	C15H14N4O
CAS Registry Number	129618-40-2
SMILES	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hepatobiliary disease	09.01.08.003	-	-	Not Available
Renal impairment	20.01.03.010	-	-	Not Available
Lipohypertrophy	23.07.01.005; 14.08.04.009	-	-
Hepatic enzyme abnormal	13.03.04.026	-	-	Not Available
Immune reconstitution inflammatory syndrome	10.02.01.043; 08.06.02.014	0.002652%		Not Available
Treatment failure	08.06.01.017	0.013791%		Not Available
Liver injury	12.01.17.012; 09.01.07.022	-	-	Not Available
Low birth weight baby	18.04.02.003	0.002652%		Not Available
Oral disorder	07.05.01.005	-	-	Not Available
Traumatic liver injury	12.01.17.027; 09.01.08.010	-	-	Not Available
Hypertransaminasaemia	09.01.02.005	-	-	Not Available
Drug-induced liver injury	12.03.01.044; 09.01.07.023	0.010608%		Not Available
Drug reaction with eosinophilia and systemic symptoms	23.03.05.005; 10.01.01.021; 12.03.01.064	0.002652%		Not Available
Enthesopathy	15.07.01.011	0.010608%		Not Available
Neonatal asphyxia	22.11.02.006; 18.04.15.005	0.005304%		Not Available
Neonatal respiratory distress syndrome	22.11.02.010; 18.04.10.003	0.002652%		Not Available
Lip erosion	07.05.06.011	0.002652%		Not Available
Graves' disease	10.04.08.014; 06.09.04.009; 05.02.02.009	-	-	Not Available
Hyperplasia adrenal	14.11.01.052; 05.01.03.005	0.003978%		Not Available
Treatment noncompliance	12.09.02.006; 08.06.01.067	0.006630%		Not Available

The 6th Page First Pre 6 Total 6 Pages